Ahmed 2020.

Study characteristics
Methods	Trial design: double‐blind RCT with 3 parallel arms, only 2 arms relevant; the third arm investigated ivermectin plus another active treatment (doxycycline) Type of publication: journal publication Setting: inpatient Recruitment dates: NR Country: Bangladesh Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NA Date of registration: NA
Participants	Number of participants (randomized/analyzed): 72/68 (relevant arms: 48/45) Age (mean): overall 42 (SD NR) years Males, n: overall 33 (46%) Severity of condition according to study definition: hospitalized, no participants required oxygen Severity of condition according to WHO scale: 4 Co‐morbidities: NR Virus detection performed at baseline (test‐positive at baseline): RT‐PCR (100%) Inclusion criteria: aged 18–65 years; admitted to hospital within last 7 days; presence of fever (37.5 °C), cough, sore throat, or a combination; diagnosed positive for SARS‐CoV‐2 by rRT‐PCR Exclusion criteria: allergic to ivermectin or doxycycline, or if here was the potential for a drug–drug interaction with ivermectin or doxycycline; had chronic illnesses (e.g. ischaemic heart disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease); had received ivermectin or doxycycline (or both) in the last 7 days; were pregnant or lactating; or had participated in any other clinical trial within last month
Interventions	Details of intervention for relevant arms Type and dose: ivermectin 12 mg, once daily for 5 days Route of administration: oral Treatment details of control group  Placebo Concomitant therapy: NA Duration of follow‐up: NR Treatment cross‐overs: none
Outcomes	Primary study outcome Time to viral clearance Remission of fever and cough within 7 days Relevant review outcomes reported Worsening of clinical status (need for oxygen) at 14 days Serious adverse events within 14 days Duration of hospitalization Viral clearance (RT‐PCR) at 3, 7, and 14 days Additional study outcomes reported Proportion of participants with remission of fever, cough, and sore throat Time to viral clearance (hazard ratio) Blood biomarkers were measured on enrolment and on day 7 CRP, ferritin, LDH, and procalcitonin)
Notes	Date of publication: 2 December 2020 Sponsor/funding: Beximco Pharmaceutical Limited, Bangladesh Correspondence with the author team: author request sent (follow‐up period for serious adverse events and mortality, details on baseline characteristics); no response received from author Information on ethics votum: name of responsible ethics committee reported; no reference number of proposal or votum provided in publication. Sent author request; no response received